Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Jasper Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 42 | 61 | +19 |
| Shares | 75.5M | 13.0M | −62.5M (−82.7%) |
| Value | $61.2M | $380.2M | +$319.0M (+521.3%) |
New holders (33)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (14)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Nantahala Capital Management, LLC | 2,228,265 | $1.76M |
| Saturn V Capital Management LLC | 1,386,215 | $1.09M |
| Renaissance Technologies LLC | 514,324 | $406.0K |
| Monaco Asset Management SAM | 249,563 | $196.9K |
| Cowen and Company, LLC | 200,000 | $157.8K |
| Summit Trail Advisors, LLC | 65,000 | $51.3K |
| Ieq Capital, LLC | 54,500 | $43.0K |
| Two Sigma Investments, LP | 54,168 | $42.7K |
| Bank of New York Mellon Corp | 43,593 | $34.4K |
| Charles Schwab Investment Management Inc | 36,899 | $29.1K |
| Gries Financial LLC | 23,845 | $18.8K |
| Tower Research Capital LLC (TRC) | 11,144 | $8.79K |
| Group One Trading, L.P. | 1 | $1 |
| Cutler Group LP | 1,200 | $0 |